The company's move toward obscure diseases accelerated when Vasella lured Harvard cardiologist Mark Fishman in 2003 to run research from a new lab in Cambridge, Mass.

FORBES: Magazine Article

Harvard Professor Mark Fishman , who will leave his academic perch to run Novartis' Cambridge-based laboratory, believes that in the future most biological research will be possible both in drug companies and in academia, but some sliver of basic biology will still need to be done solely in academia.

FORBES: Magazine Article